Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mr. Gregory J. Davis

Vice President of Corporate and Business Development

Mr. Jerad G. Seurer

General Counsel & Company Secretary

Mr. Thomas S. McHugh

Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer

Mr. Gregory J. Divis Jr.

Chief Executive Officer & Director

Mr. Richard J. Kim

Chief Commercial Officer

Mr. Mark W. Elrod

Vice President of Sales

Ms. Angie  Woods

Vice President of People & Culture

Dr. Jordan S. Dubow M.D.

Consultant

Dr. Jason M. Vaughn

Senior Vice President of Technical Operations

Ms. Jennifer  Gudeman PharmD

Senior Vice President of Medical & Clinical Affairs

Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc Struttura manageriale

Informazioni sul management